EDF Ventures EDF Ventures is a leading venture capital firm investing in early-stage healthcare companies. Our partners bring deep domain knowledge, extensive networks and a distinguished track record to every endeavor. Testimonials Featured Portfolio Company News Lycera Announces Initiation of Phase 2 Clinical Trial of LYC-30937-EC in Patients with Ulcerative Colitis Lycera Congratulates Dr. Peter L. Toogood for His Receipt of the 2016 Heroes of Chemistry Award from the American Chemical Society (ACS) Lycera Announces Progress in Immuno-Oncology Program Presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting Lycera Announces Presentations of Positive Preclinical Results for Lead Candidate LYC-30937 and for Selective Rho kinase Inhibitor Program at the 11th Congress of the European Crohn's and Colitis Organization (ECCO) IntelePeer Provides Near-Real Time Provisioning for Cisco Spark Call via its new API Lycera Announces Celgene Has Exercised its Option to License Portfolio of Ex Vivo RORgamma Agonist Compounds under Global Strategic Collaboration Lycera Corp Expands Leadership Team, Appoints Alex G. Howarth as Chief Financial Officer Lycera and Celgene Announce an Exclusive Strategic Collaboration to Advance Novel Immune Modulators Direct Flow Medical Names Daniel Lemaitre as Chief Executive Officer Lycera Initiates Phase 1 Clinical Trial of LYC-30937, a First-In-Class ATPase Modulator for Inflammatory Bowel Disease Lycera Announces Milestone in Merck Collaboration Cerenis Therapeutics launches its IPO on the Euronext regulated market in Paris Lycera Expands Leadership Team, Names H. Jeffrey Wilkins, M.D., as Chief Medical Officer Please do not submit any information or other materials that you consider to be confidential or proprietary. Because of the large number of business plans and related materials that EDF Ventures reviews, and the similarity of many such plans and materials, EDF Ventures cannot accept responsibility for protecting against misuse or disclosure of any confidential or proprietary information or other materials in the absence of EDF Ventures' express written agreement to do so. Terms | Privacy